Edgeline Holdings Agrees to Terms for an Exclusive Worldwide Right to Option Patents Covering the Composition and Use of Genistein Analogs for Cancer Treatment

HOUSTON--(BUSINESS WIRE)--Edgeline Holdings, Inc. (OTCBB:ELHI), which recently announced a name change to Oncolin Therapeutics, Inc., announces that it has agreed to terms for an exclusive worldwide right to option patents covering the composition and use of Genistein analogs for cancer treatment. The technology was discovered and patented by the Pharmaceutical Research Institute of Warsaw, Poland and involves compounds that appear to be novel antimicrotubule agents.